<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364779">
  <stage>Registered</stage>
  <submitdate>20/08/2013</submitdate>
  <approvaldate>30/08/2013</approvaldate>
  <actrnumber>ACTRN12613000966796</actrnumber>
  <trial_identification>
    <studytitle>Effect of lycosome-formulated dark chocolate on serum lipid profile and parameters of cardiovascular health</studytitle>
    <scientifictitle>Effect of lycopene-containing lycosome-formulated dark chocolate on lipid profile and parameters of cardiovascular health in pre-hypertensive and hyperlipidemic individuals</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nill</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>hypertension</healthcondition>
    <healthcondition>hyperlipidemia</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Alternative and Complementary Medicine</conditioncode1>
      <conditioncode2>Other alternative and complementary medicine</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Hypertension</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A proprietary dark chocolate formulation (L-tug dark chocolate) containing lycopene, a carotenoid compound embedded into cocoa butter micelles  being studied.
Arm 1. Effect of L-tug dark chocolate on blood pressure in pre-hypertensive  volunteers.
Arm 2. Effect of L-tug dark chocolate on lipid profile in  hyperlipidemic volunteers.
In both arms of the trial volunteers will be given once daily10 g of L-tug dark chocolate bar  containing 7 mg of lycopene embedded into its matrix. Duration of the intervention will be 4 weeks. Adherence to the protocol will be controlled by measuring the cocoa flavanols concentration in the plasma specimens collected at the end point of the study.</interventions>
    <comparator>L-tug dark chocolate with no lycopene (10 g bar given orally once daily).</comparator>
    <control>Placebo</control>
    <interventioncode>Other interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>reduction in the systemic blood pressure &gt; 4 mmHg as measured by an automatic sphygmomanometer</outcome>
      <timepoint>each participant will be evaluated  in 2 and 4 weeks from start of the intervention</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>reduction in serum LDL cholesterol &gt;10 mg/dl</outcome>
      <timepoint>each participant will be evaluated  in 2 and 4 weeks from the start of intervention</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>reduction in serum triglycerides </outcome>
      <timepoint>end of the 4th week of the intervention</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>improved artherial flow as measured by doppler ultrasound protocol</outcome>
      <timepoint>end of the 4th weeks of the intervention</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Arm 1. Increased systemiic blood pressure in pre-hypertension range (systolic pressure 120-139 mmHg, diastolic - 80-89 mmHg)
Arm 2. Moderate increase in serum total  cholesterol (200-239 mg/dl)</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>food allergies, obesity, alcoholism</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>central randomisation by phone/fax/computer</concealment>
    <sequence>Simple randomisation using a randomisation table created by computer software (i.e. computerised sequence generation).</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>Study is designed on an intention-to-treat basis. A pilot trial was performed as validation study for sample size evaluation. It was determined using one-tailed t-test that 80 individuals will satisfy the statistical requirements for data analysis and test feasibility of the intervention compared to the placebo group. Association between trial outcome and specific study arms of the study will be analyzed by multivariable analysis.
Categorical values will be analyzed by Stata 12 and MedCalc software. Continuous variable will be compared using the Mann-Whitney U-test. Linear regression analysis will be performed for both arms of the study. A p-value threshold is set at &lt;0.05 to claim statistical significance.
</statisticalmethods>
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>False</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>26/08/2013</anticipatedstartdate>
    <actualstartdate>16/08/2013</actualstartdate>
    <anticipatedenddate>23/09/2013</anticipatedenddate>
    <actualenddate />
    <samplesize>80</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saratov Region</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cambridgeshire</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Lycotec Ltd, United Kingdom</primarysponsorname>
    <primarysponsoraddress>Granta Park, Platinum Bldg, Cambridge, Cambridgeshire,
United Kingdom, CB21 6GP </primarysponsoraddress>
    <primarysponsorcountry>United Kingdom</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Lycotec Ltd</fundingname>
      <fundingaddress>Granta Park, Platinum Bldg,
Cambridge, Cambridgeshire, CB21 6GP </fundingaddress>
      <fundingcountry>United Kingdom</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Government body</sponsortype>
      <sponsorname>Institute of Cardiology, Saratov, Russian Federation</sponsorname>
      <sponsoraddress>Institute of Cardiology, 12 Chernyshevskogo Str, 410028 Saratov, Russia</sponsoraddress>
      <sponsorcountry>Russian Federation</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Dark chocolate flavanols and lycopene are potent nutraceuticals with variety of effects on cardiovascular system.
L-tug, a novel formulation of dark chocolate with an improved bioavailability of cocoa flavanols, has been shown in preliminary studies to reduce both the systemic blood pressure and serum lipids. The primary purpose of the trial is to verify the reproducibility and statistical significance of blood pressure and serum lipid reductions in suitable cohorts of  healthy volunteers. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Medical Research Ethical Committee, Institute of Cardiology</ethicname>
      <ethicaddress>Institute of Cardiology, 12 Chernyshevskogo Str, 410028 Saratov, Russia</ethicaddress>
      <ethicapprovaldate>10/07/2013</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>5/06/2013</ethicsubmitdate>
      <ethiccountry>Russian Federation</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Ivan Petyaev</name>
      <address>Lycotec Ltd ,Platinum Building,  Granta Park Campus, Cambridge, Cambridgeshire,  CB21 6GP </address>
      <phone>+44 (0) 1954 212838</phone>
      <fax />
      <email>ykb75035@aol.com</email>
      <country>United Kingdom</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Ivan Petyaev</name>
      <address>Lycotec Ltd, Platinum Building,  Granta Park Campus, Cambridge, Cambridgeshire, CB21 6GP </address>
      <phone>+44 (0) 1954 212838</phone>
      <fax />
      <email>ykb75035@aol.com</email>
      <country>United Kingdom</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Yuriy Bashmakov </name>
      <address>Lycotec Ltd, Platinum Building, Granta Park Campus, Cambridge, Cambridgeshire, CB21 6GP </address>
      <phone>+44 (0) 1954 212838</phone>
      <fax />
      <email>yuriy.bashmakov@lycotec.com</email>
      <country>United Kingdom</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>